Big Pharma Update: What Big Pharma is Looking for In Partnering Opportunities
Thus far, 2009 has marked unprecedented changes and challenges within the biotechnology industry. Big pharma has responded to these challenges through mega mergers, high-profile consolidations, and high-value licensing deals. Couple this with Congress' impending health care reform measures and pressure to lower drug prices along with changes at the FDA, it is no wonder big pharma is taking dramatic steps to protect and enhance their opportunities for long-term growth. Small to medium-sized life sciences companies have also been forced to make changes as they struggle to retain value, maximize market potential and reduce risks.
In this session, panelists will explore:
- What investment and partnering opportunities are of top priority in the short term?
- Forward looking perspectives about investment and partnering priorities in the future
- Steps small and medium-sized life sciences companies should take to retain and enhance value
Moderator
-
Michael Gunning , Assurance Partner, Pricewaterhouse Coopers
Panelists:
- Roy Cosan, Vice President, Johnson & Johnson Development Corporation
- Stephen B. Maebius, Partner, Foley & Lardner LLP
- Linda Pullan, Ph.D., Pullan Consulting
- James M. Schaeffer, Worldwide Licensing and External Research-West Coast, Merck & Company